2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363-85.
3. Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018;10:1758835918794630.
4. Morgan TM. Liquid biopsy: Where did it come from, what is it, and where is it going? Investig Clin Urol 2019;60:139-41.
5. Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision medicine. Cancer Res 2019;79:2798-804.
6. Casanova-Salas I, Athie A, Boutros PC, et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur Urol 2021;79:762-71.
7. Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY, Roehrl MHA, Barrera-Saldaña HA. The dawn of the liquid biopsy in the fight against cancer. Oncotarget 2018;9:2912-22.
8. Li D, Lai W, Fan D, Fang Q. Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies. Am J Physiol Cell Physiol 2021;321:C779-97.
9. Werner S, Keller L, Pantel K. Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. Mol Aspects Med 2020;72:100817.
10. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-7.
11. Lennon AM, Goggins M. Diagnostic and therapeutic response markers, Pancreatic Cancer. New York, NY: Springer, 2010; pp. 675-701.
12. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
13. Bhardwaj M, Gies A, Werner S, Schrotz-King P, Brenner H. Blood-based protein signatures for early detection of colorectal cancer: a systematic review. Clin Transl Gastroenterol 2017;8:e128.
14. Yang D, Zhang X, Powell CA, et al. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study. Cancer 2018;124:262-70.
15. Hsu T, Liu T, Gould B, et al. Abstract PO-007: plasma-based detection of pancreatic cancer: A multiomics approach. Cancer Res 2021;81:PO-007.
16. Cai Z, Zhang J, He Y, et al. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma. ESMO Open 2021;6:100021.
17. Guo D, Sun J, Wang Y, et al. 956P A multi-analyte liquid biopsy assay integrating cfDNA methylation and protein biomarkers for liver cancer diagnosis. Ann Oncol 2021;32:S828.
18. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-78.
19. Wroclawski ML, Serpa-Neto A, Fonseca FL, et al. Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumour Biol 2013;34:2921-7.
20. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926-30.
21. Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening - a perspective on the current state of the evidence. N Engl J Med 2017;376:1285-9.
22. Kleif J, Ferm L, Davis GJ, Christensen IJ, Nielsen HJ. 898 Development of blood-based, cancer-associated biomarkers for early detection of colorectal cancer: significant differences between results from symptomatic and screening subjects. Gastroenterology 2020;158:S-1538.
23. Wen YH, Chang PY, Hsu CM, Wang HY, Chiu CT, Lu JJ. Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: results from a 12-year experience. Clin Chim Acta 2015;450:273-6.
24. Chung S. False-positive elevations in carcinoembryonic antigen levels at a health screening center. Lab Med Online 2019;9:146.
25. Wang HY, Hsieh CH, Wen CN, Wen YH, Chen CH, Lu JJ. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers. PLoS One 2016;11:e0158285.
26. Wang HY, Chen CH, Shi S, et al. Improving multi-tumor biomarker health check-up tests with machine learning algorithms. Cancers (Basel) 2020;12:1442.
28. Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA. Tumour Biol 2018;40:1010428318776169.
29. Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol 2019;14:343-57.
30. Cargnin S, Canonico PL, Genazzani AA, Terrazzino S. Quantitative analysis of circulating cell-free DNA for correlation with lung cancer survival: a systematic review and meta-analysis. J Thorac Oncol 2017;12:43-53.
31. Qvick A, Stenmark B, Carlsson J, Isaksson J, Karlsson C, Helenius G. Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer. Mol Med 2021;27:68.
32. Tissot C, Toffart AC, Villar S, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J 2015;46:1773-80.
33. González de Aledo-Castillo JM, Casanueva-Eliceiry S, Soler-Perromat A, et al. Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients. Eur J Nucl Med Mol Imaging 2021;48:3631-42.
34. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 2017;7:1394-403.
35. Phallen J, Leal A, Woodward BD, et al. Early noninvasive detection of response to targeted therapy in non-small cell lung cancer. Cancer Res 2019;79:1204-13.
36. Sestini S, Boeri M, Marchiano A, et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget 2015;6:32868-77.
37. Liu MC. Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future prospects. Br J Cancer 2021;124:1475-7.
38. Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clin Chem Lab Med 2021;59:1353-61.
39. Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020;369:eabb9601.
40. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020;31:745-59.
41. Wan N, Weinberg D, Liu TY, et al. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. BMC Cancer 2019;19:832.
42. Lin J, Ariazi E, Dzamba M, et al. Evaluation of a sensitive blood test for the detection of colorectal advanced adenomas in a prospective cohort using a multiomics approach. JCO 2021;39:43-43.
43. Ulz P, Perakis S, Zhou Q, et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat Commun 2019;10:4666.
44. Putcha G, Gutierrez A, Skates S. Multicancer screening: one size does not fit all. JCO Precis Oncol 2021;5:574-6.
45. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically meaningful use of blood tumor markers in oncology. Biomed Res Int 2016;2016:9795269.
46. McKeegan EM, Ansell PJ, Davis G, et al. Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib. Lung Cancer 2015;90:296-301.
48. Lamb YN, Dhillon S. Epi proColon((R)) 2.0 CE: a blood-based screening test for colorectal cancer. Mol Diagn Ther 2017;21:225-32.
49. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-97.
50. Guler GD, Ning Y, Ku CJ, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun 2020;11:5270.
51. Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection. Trends Cancer 2017;3:198-213.
52. Hemken PM, Sokoll LJ, Yang X, et al. Validation of a novel model for the early detection of hepatocellular carcinoma. Clin Proteomics 2019;16:2.
53. Yang JD, Addissie BD, Mara KC, et al. GALAD Score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 2019;28:531-8.
54. Yang T, Xing H, Wang G, et al. A Novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin Chem 2019;65:1543-53.
Comments
Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.